← Back to Search

GLP-1 Receptor Agonist

Cohort 2 for Type 1 Diabetes

Phase 1
Waitlist Available
Research Sponsored by Hanmi Pharmaceutical Company Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
T1DM or T2DM
Female subjects must be non-pregnant and non-lactating
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month
Awards & highlights

Study Summary

This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 1 and Type 2 diabetes mellitus

Eligible Conditions
  • Type 1 Diabetes
  • Type 2 Diabetes

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check β€œYes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with adverse events
Secondary outcome measures
AUC of HM12470
Cmax of HM12470

Trial Design

4Treatment groups
Experimental Treatment
Group I: Cohort 4Experimental Treatment1 Intervention
T2DM: Multiple dose subcutaneous administration
Group II: Cohort 3Experimental Treatment1 Intervention
T2DM: Multiple dose subcutaneous administration
Group III: Cohort 2Experimental Treatment1 Intervention
T1DM: Multiple dose subcutaneous administration
Group IV: Cohort 1Experimental Treatment1 Intervention
T1DM: Multiple dose subcutaneous administration
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
HM12470
2015
Completed Phase 1
~160

Find a Location

Who is running the clinical trial?

Hanmi Pharmaceutical Company LimitedLead Sponsor
188 Previous Clinical Trials
60,975 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~6 spots leftby Mar 2025